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HIV-1 Tat protein binds to TLR4-MD2 and signals
to induce TNF-α and IL-10
Nawal Ben Haij1,2,3, Kaoutar Leghmari1,2,3, Rémi Planès1,2,3, Nathalie Thieblemont4,5 and Elmostafa Bahraoui1,2,3*
Abstract
Background: HIV-1 infection results in hyper-immune activation and immunological disorders as early as the
asymptomatic stage. Here, we hypothesized that during early HIV-1 infection, HIV-1 Tat protein acts on monocytes/
macrophages to induce anti-inflammatory and proinflammatory cytokines and participates in immune dysregulation.
Results: In this work we showed that Tat protein: i) by its N-terminal domain induces production of both IL-10 and
TNF-α in a TLR4-MD2 dependent manner, ii) interacts specifically with TLR4-MD2 and MD2 with high affinity but not
with CD14, iii) induces in vivo TNF-α and IL-10 in a TLR4 dependent manner.
Conclusions: Collectively, our data showed for the first time that, HIV-1 Tat interacts physically with high affinity with
TLR4-MD2 to promote proinflammatory cytokines (TNF-α) and the immunosuppressive cytokine IL-10 both involved in
immune dysregulation during early HIV-1 infection and AIDS progression.
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Background
HIV-1 infects numerous cells of the immune system, essen-
tially CD4 T-cells, monocytes/macrophages and, to a lesser
extent, dendritic cells [1] leading to the establishment of a
persistent chronic hyper-immune activation [2]. As conse-
quence, this abnormal hyperstimulation inevitably leads to
the weakening of the immune system that facilitates HIV-1
replication, virus persistence and AIDS disease progression
[2-4]. HIV-1 immune activation is associated with the
production of several cytokines, including TNF-α, a
pro-inflammatory cytokine, and IL-10, a highly immuno-
suppressive cytokine, two cytokines that have been involved
in the immune dysregulation observed in HIV-1 infected
patients [5]. Indeed, HIV-1 is able to activate cells of the
innate immune system via various pathways. By its nucleic
acids, HIV-1 activates Toll-like receptor 7/8 (TLR7/8) and
TLR3 to activate innate signaling of HIV-1 infected cells
and to induce proinflammatory cytokines, including TNF-α
and type I IFNs, that contribute to immune activation and
viral replication [6-8]. At least 10 TLR have been reported
in humans and 13 in mice [9], expressed by the cells of the
immune system. Like TLR, other innate immune pattern
recognition receptors (PRR), that play an essential role in
the initiation of the innate and adaptive immune responses,
including NOD-like receptors (NLR), RIG-like receptors
(RLR) and C-type lectin receptors (CLR), also recognize
conserved pathogen-associated molecular patterns (PAMP)
to activate proinflammatory cytokines and chemokines [9].
Our group [10-13] and others [14,15] have shown that
HIV-1 Tat protein is able to stimulate proinflammatory
(IL1-β, IL-6, IFN-γ, TNF-α) and anti-inflammatory (IL-10)
cytokines in human monocytes/macrophages. Tat protein
is an 86 to 104 amino-acids polypeptide of 14 kDa, known
for its crucial transactivation activity of HIV-LTR [16].
Tat protein is structured in several domains including
the N-terminal region 1–47 and the basic region, which
is essential for Tat internalization, nuclear localization and
RNA binding at the LTR-TAR region [17]. Tat protein is
found at nM levels in the serum of HIV-1 infected patients
[18-20]. However, taking into account that a fraction of
Tat protein remained adsorbed on the cell surfaces, the
determined soluble Tat concentration is probably underes-
timated and could be much larger near the lymphoïd
organs and in the vicinity of infected cells [21].
Beside its crucial role in activating viral replication, Tat
also participates in the pathogenesis of HIV-1 infection
by its capacity to interact with infected or not infected
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cells [22]. Tat also, contributes to the spread of HIV-1
through its effect on the increase of CCR5 and CXCR4
surface expression [23]. Tat has been found to induce
neurotoxicity in the central nervous system [24,25] and
apoptosis in CD4 T-cells [26]. Moreover, several studies
suggest a direct effect of Tat protein in the structural and
immunological dysfunctions observed early after infection,
in the gastrointestinal tract (GALT) from HIV-1 infected
patients [2]. Indeed, it was reported that Tat protein can
act directly on the GALT, by impairing intestinal glucose
absorption [27] or indirectly by boosting abnormaly
immune activation, which is exacerbated later following the
breakdown of the mucosal barrier and the translocation of
the bacterial product into the blood [2].
While some of Tat effects are mediated after intracellular
uptake of Tat, others are mediated by the interaction of
extracellular Tat with cellular receptors. Different domains
of Tat have been implicated in interactions with membrane
receptors: the N-terminal region with CD26 receptor [28]
and L-Type calcium channel [29] the tripeptide RGD with
integrin αvβ3 and α5β1 of dendritic cells [30], and the basic
domain with membrane lipids [25] or with the Flk-1/KDR
receptor [31]. Among these potential Tat receptors, it
would be of importance to determine which receptor(s)
participate to the activation of signalling pathways that
lead to the production of proinflammatory and anti-
inflammatory cytokines, reported by our group and others,
which seem to be strongly involved in the abnormal
immune activation and immune dysregulation.
In this study, we advance TLR4 as a potential candidate
receptor for Tat protein for the following reasons: i) Tat
protein induces the production of TNF-α and IL-10 by
human monocytes/macrophages by acting at the cell
membrane level, ii) TLR4 is expressed on the surface
of monocytes/macrophages, iii) the signalling pathways
activated by Tat, including MAPkinases, PKC and NF-κB
[11] are also activated following the engagement of the
TLR4 pathways [32].
Our results presented in this study, showed that Tat
protein induced TNF-α and IL-10 production in mono-
cytes-macrophages from human and mice cells but not in
macrophages from TLR4 KO mice. Further we showed
that Tat protein by its N-terminal domain 1–45 interacts
with high affinity with TLR4-MD2 receptor on human
monocyte-macrophage cells to induce TNF-α and IL-10,
two cytokines implicated in the hyperactivation and
dysregulation of the immune system in HIV-1 infected
patients.
Results
Tat protein induces the production of TNF-α and IL-10 by
acting at cell membrane level in human monocytes
Tat protein contains a nuclear localization sequence
between amino acids 49 and 57 which allows it to be
taken up by cells into the nucleus. Thus, Tat protein
could act at either the membrane and/or the nucleus
level. Previously, we showed that stimulation of human
monocytes with synthetic or recombinant proteins,
GST-Tat 1-101 or GST-Tat 1–45, but not GST-Tat 30–72
or GST alone, activated the production of TNF-α and
IL-10 [11].
In addition, we previously showed that Tat oxidation
by H2O2, its trypsin digestion or heating (5 min at 95°C)
totally abolished the capacity of Tat to induce the pro-
duction of TNF-α and IL-10, while such treatments had
no effect on the capacity of LPS to stimulate the production
of these cytokines [11]. Using the LAL assay, we showed
that the Tat protein used in this work contained no endo-
toxins within the limit of detection of the test (less than
50 pg/ml). Likewise, LPS at 50 pg/ml did not cause the
production of TNF-α and IL-10 in our experiments. All
these characterizations exclude contamination with endo-
toxins and indicate the direct implication of Tat protein,
by acting at the cell membrane surface, by its N-terminal
domain to induce the TNF-α and IL-10 production.
Tat protein induces TLR4-dependent cytokine production
in human monocytes
To investigate the role of TLR4-MD2 as a potential
receptor implicated in the production of TNF-α and
IL-10 by Tat, we evaluated the inhibitory effect of the
anti-TLR4 blocking monoclonal antibody (Mab), clone
HTA125, on Tat-induced cytokine production. To this
end, primary human monocytes were pretreated with
increasing amounts of anti-TLR4 Mab (0.01–1 μg/ml) be-
fore stimulation by Tat. In these conditions anti-TLR4 anti-
bodies inhibited Tat-induced cytokine in a dose dependent
manner (Figure 1A-B). Total inhibition was obtained with
anti-TLR4 Mab at 1 μg/ml. Similarly, when monocytes
were pretreated with saturating amount of anti-TLR4
antibodies (1μg/ml) and then stimulated with increasing
concentrations of Tat 1–101 (1–100 nM) or its deleted
mutants Tat 1–45, strong inhibition of TNF-α and IL-10
were observed (Figure 1C-D). No inhibition was observed
when Tat stimulation was performed in the presence of
anti-TLR2 or with irrelevant IgG antibodies harbouring
the same isotype as HTA125 Mab in control experiments
(Figure 1A). More interestingly, we showed that LPS-RS
(from Rhodobacter Sphaeroides), previously described as a
potent antagonist of LPS [33], is also able to block the
ability of Tat to induce TNF-α and IL-10 production
(Figure 1E). Finally, as expected, we showed that HTA125
Mab also totally inhibited LPS-induced cytokine production
(Additional file 1: Figure S1).
Altogether, these results indicate that Tat induces TLR4-
dependent production of IL-10 and TNF-α in human
monocytes.
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HIV-1 Tat protein interacts physically with TLR4-MD2
Taking these data into consideration, we investigated the
capacity of Tat to interact directly with TLR4 and its
cofactors MD2 and CD14. MD2 is a soluble glycosylated
polypeptide of 160 amino acids which associates with
high affinity to the ectodomain of TLR4, while CD14 is
Figure 1 HIV-1 Tat-protein-induced TNF-α and IL-10 is TLR4-dependent. A-B) Monocytes were pretreated or not with increasing amounts of
blocking antibodies against TLR4 or TLR2 or isotype control for 1h before stimulation by GST-Tat 1–101. C) Mab anti-TLR4 (1 μg/ml) were incubated for
1 h with 106 human monocytes before stimulation with 1, 10 or 100 nM of Tat or with, D) 100 nM of GST-Tat 1–101, GST-Tat 1–45, or GST-Tat 30–72.
GST was used as a control. After 24 h, TNF-α and IL-10 in the supernatant (SN) were measured by ELISA. After 24 h, TNF-α and IL-10 were measured in
the SN. The values are representative of three independent experiments. E) Monocytes were treated with LPS (1 ng/ml) or GST-Tat1-101 (10 nM) in the
presence or not of LPS-RS (1 μg/ml). After 24 h, TNF-α and IL-10 were quantified in the culture supernatant by ELISA. Data represent means +/− SD.
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a glycosylphosphatidylinositol (GPI) membrane glycopro-
tein of 375 amino-acids which seems to play an important
role in the trafficking of TLR4 and other receptors, includ-
ing TLR3, TLR7 and TLR9 [34].
To investigate whether Tat was able to interact physically
with TLR4-MD2 complex, MD2 or CD14 recombinant
proteins were tested for their capacities to interact, in a
solid phase assay, with HIV-1 Tat protein or its deleted
mutants Tat 1–45 and Tat 30–72. The results depicted in
Figure 2A show a direct interaction of Tat with TLR4-
MD2 or with MD2 alone. In contrast, no interaction was
observed between Tat and CD14 (Figure 2A). As control,
when GST was used, no binding with TLR4-MD2 or MD2
was detected (Figure 2A). To identify the domain of Tat
implicated in this interaction, the N-terminal domain Tat
1–45 and the central domain, Tat 30–72, were tested in
the same assays. The results showed that the N-terminal
domain, Tat 1–45, as Tat 1–101, also, interacted strongly
with MD2 and TLR4-MD2, but not with CD14 (Figure 2A).
In contrast, no binding was observed with the Tat 30–72
fragment or with GST control (Figure 2A). In a parallel
assay, GST-Tat 1–101, GST-Tat 1–45, GST-Tat 30–72 and
GST previously coupled to glutathion-agarose beads, were
tested for their capacity to interact with soluble recom-
binant TLR4-MD2, MD2 or CD14. After incubation and
washes, the preformed complexes were analyzed by
SDS-PAGE and western blot. The corresponding results,
shown in Figure 2B, clearly confirmed the capacity of Tat
to interact, via its N-terminal fragment, with TLR4-MD2
and MD2, but not with CD14. In line with the binding
assay data, similar results were obtained when the same
experiments were performed using, as source of TLR4/
MD2/CD14 cell lysate proteins prepared from HEK293
cells stably transfected withTLR4-CD14-MD2 (Figure 2C).
Non-transfected HEK cells were used as controls
(Figure 3C). In addition, recombinant GST-Tat pro-
teins (Additional file 2: Figure S2A) and recombinant
TLR4, MD2 and CD14 (Additional file 2: Figure S2C)
were characterized by SDS-PAGE. Further we have
evaluated the native-like conformations of TLR4 and
MD2 by demonstrating, in a binding assay, their cap-
acity to interact physically and in a dose dependent
manner (Figure 2D).
In order to demonstrate the specificity of Tat-TLR4-MD2
interactions, Tat-MD2 or Tat-TLR4-MD2 interactions were
further analyzed in a molecular binding assay. Binding
was performed in the presence of various concentrations
of MD2, TLR4-MD2 or Tat. The results in (Additional
file 3: Figure S3A-B), show that Tat (1 μM) binds to MD2
(1 pg/mL to 1μg/mL) in a dose dependent manner, with a
clear saturation plateau. Similarly, the binding of MD2 (10
ng/mL) to increasing amounts of Tat (10-11 to 10-6 M)
showed that the formation of Tat-MD2 or Tat-TLR4-MD2
complexes were dependent on the Tat concentrations,
with a saturation plateau at 10-6 M of Tat (Additional
file 3: Figure S3C-D).
The specificity of Tat-MD2 and Tat-TLR4-MD2 inter-
actions were further characterized by testing the capacity
of soluble MD2, TLR4-MD2, TLR4 or CD14 to compete
for these interactions. The results depicted in Figure 2E,
clearly show the capacity of soluble MD2 (100 pg - 1 μg)
to inhibit the binding of Tat to coated MD2 in a dose
dependent manner (Figure 2E). Strong inhibition (more
than 95%) was obtained with soluble MD2 used at 1 μg/ml.
The concentration of soluble MD2 (K0.5) capable of inhibit-
ing Tat-MD2 interaction by 50% was about 4.10-9 M. This
value of K0.5, which can be considered as an apparent
dissociation constant, indicates that Tat recognizes MD2
with a relatively high affinity. In agreement with the direct
binding data, soluble TLR4-MD2 is also able to totally
inhibit Tat-MD2 or Tat-TLR4-MD2 interactions when
used at 1 μM (Figure 2E). The K0.5 of TLR4-MD2, about
10-9 M, is 2.5 times less than that obtained with MD2
alone, suggesting a higher affinity of MD2, for Tat, when it
is associated with TLR4. In contrast, when soluble TLR4 or
CD14 were used as competitors, no significant inhibitions
were observed (Figure 2E). Similar results were obtained
when soluble TLR4-MD2, TLR4, or CD14 were used to
compete for MD2-Tat 1–45 interaction (Additional file 3:
Figure S3).
Then we wondered whether Tat protein was able to
bind and to localize with TLR4 at the cell surface of HEK
cells stably transfected with TLR4-MD2-CD14. Non-
transfected HEK cells, HEK Null, were used as negative
controls. To this end, Tat-TLR4-MD2 interaction was
labelled with stained anti-Tat (Tat-555) and anti-TLR4
(TLR4-488) antibodies and complex formation was ana-
lyzed by confocal microscopy (Figure 3). Briefly, cells were
incubated or not with Tat, and then labelled with anti-Tat
or anti-TLR4 antibodies, separately or in a mixture. The
results showed that Tat protein and its N-terminal fragment
Tat 1–45 were able to bind to HEK-TLR4-MD2-CD14 cells
but not to HEK Null (Figure 3). This labeling was specific
since no staining was observed when experiments were
performed after: i) incubating cells with the same amount
of soluble GST protein instead of Tat (Figure 3), ii) omitting
the primary antibody or iii) using an isotype control instead
of anti-Tat antibodies (data not shown). This co-presence
is also in agreement with the ability of Tat to interact
physically with TLR4-MD2 in the inhibition and the bio-
chemical binding assays previously described.
Tat protein fails to stimulate TNF-α and IL-10
in macrophages from TLR4−/− mice
To confirm the involvement of Tat-TLR4 interaction in
the signalling pathways leading to cytokine production, we
used genetically engineered mice deficient in various TLR
or their cofactors, including MD2 and CD14. Firstly, we
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validated the ability of Tat protein to stimulate the pro-
duction of TNF-α and IL-10 in peritoneal macrophages.
Our results showed that Tat protein and its N-terminal
Tat 1–45, but not Tat 30–72, stimulated specifically and in
a dose dependent manner TNF-α and IL-10 production in
murine wt macrophages (Figure 4A-B). In agreement with
the implication of TLR4-MD2, we showed that, when
murine macrophages from TLR4−/− mice were stimulated
in the same conditions, no production of TNF-α and IL-10
was observed (Figure 4C-D). Similar results were obtained
with macrophages from C3H/HeJ mice, which have a
missense mutation in the third exon of TLR4 (Additional
file 4: Figure S4). In accordance with the selective involve-
ment of TLR4, our results showed that Tat protein and Tat
1–45, continued to stimulate TNF-α and IL-10 production
in macrophages from mice deficient for TLR2−/− TLR3−/−,
TLR7−/− or TLR9−/− (data not shown). As a positive con-
trol we showed that TLR2 pathway was not altered in mac-
rophages obtained from TLR4 KO mice as shown by
cytokines production following stimulation with Pam3CsK4
ligand (Figure 4C-D). Most interestingly, in vivo data,
showed that intraperitoneal administration of Tat protein
leads to the production of TNF-α and IL-10 in the periton-
eal washes of wt mice whereas these cytokines were greatly
reduced by 75% for TNF-α and remained undetectable for
IL-10, in TLR4 KO mice ( Figure 4I-J).
Considering the role of MD2 in the interaction with
Tat protein, we evaluated the importance of the in vivo
expression of this cofactor in the induction of the signalling
pathways leading to Tat-induced cytokine production.
Using macrophages from MD2−/− mice, we showed that
deficiency in MD2 abolished the ability of Tat to induce
the production of both TNF-α and IL-10 (Figure 4E-F).
Using the same approach, the implication of CD14 was
also evaluated by using macrophages obtained from
CD14−/− mice. Unexpectedly, despite the absence of dir-
ect Tat-CD14 interaction (Figure 2A-B), the presence of
CD14 expression seems to be essential for the activation
of TLR4-MD2 signalling pathway by Tat as shown by the
absence of cytokine production (Figure 4E-F). However,
these data seem to be in apparent contradiction with those
obtained with blockade anti-MD2 and anti-CD14 anti-
bodies, which were unable to block Tat-induced TNF-α
and IL-10 production (Figure G-H). As controls, and in
agreement with previously reported data, the same anti-
bodies completely blocked LPS-induced cytokine produc-
tion (Figure 4G-H). We also confirmed that stimulation
with LPS at relatively high concentrations restored cytokine
production in macrophages from CD14 deficient mice
(data not shown).
Altogether, our data confirm the essential implication
of TLR4 and its cofactors CD14 and MD2 in HIV-1 Tat
signalling for the production of IL-10 and TNF-α in
monocytes/macrophages.
Discussion
Several reports have shown that Tat protein is able to
bind to various cell membrane receptors [35]. However
Tat-TLR4 interaction has not been reported previously.
Numerous arguments allowed us to test this hypothesis: i)
TLR4 is expressed by human monocytes, ii) TLR4 activa-
tion induces the production of pro-inflammatory and
anti-inflammatory cytokines including TNF-α and IL-10,
by activating MAPkinases, PKC and NF-κB pathways that
we have previously demonstrated to be activated by Tat in
primary human monocytes [11], iii) TLR4 have been
reported, in addition to LPS, to interact with several
other ligands including viral proteins [34].
In agreement with this hypothesis, our results showed
that Tat-induced TNF-α and IL-10 production was strongly
inhibited in the presence of anti-TLR4 blocking antibody.
In order to be expressed at the cell surface, and func-
tional, TLR4 requires the action of several factors including
MD2 and CD14, which form complexes at the cell mem-
brane. Analysis of Tat interaction with TLR4-MD2, MD2
and CD14, by complementary approaches, showed that
Tat protein was able to interact with high affinity, with
TLR4-MD2 and MD2 but not with CD14. This binding
was totally inhibited, in a dose dependent manner, with
soluble TLR4-MD2 or MD2, thus demonstrating the
specificity of these interactions. This conclusion is also
in line with confocal microscopy analysis data, which
(See figure on previous page.)
Figure 2 Tat protein and its N-terminal fragment Tat 1–45 interact physically with TLR4-MD2 and MD2 but not with CD14. A) rh
TLR4-MD2, MD2 and CD14 were coated at 1 μg/ml in the wells. After incubation with GST-Tat 1–101, GST-Tat 1–45, GST-Tat 30–72 or GST control
(1 μM), interaction of Tat with coated rh proteins was analyzed by ELISA. The data represent OD at 450 nm and are representative of one of three
independent experiments. B-C) GST-pull down experiments: GST-Tat 1–101, GST-Tat 1–45, GST-Tat 30–72 or GST control (1 μM) coupled to
glutathione-agarose beads were incubated B) with recombinant TLR4-MD2, MD2 and CD14 (1 μg/ml) or C) with 500 μg of cellular extracts from
HEK cell expressing TLR4-MD2-CD14 or not. After washes, retained and unretained proteins fractions were evaluated by SDS-PAGE and western
blot using antibodies directed against CD14, MD2, TLR4 and GST. D) Evaluation of the capacity of recombinant TLR4 to interact with recombinant
MD2. rh TLR4 was coated at 1 μg/ml in the wells. After incubation with various concentrations of MD2 (1-10 μg/ml). TLR4-MD2 interaction was
analyzed by ELISA using anti-MD2 monoclonal antibodies. E) rhMD2 and rhTLR4-MD2 compete for Tat-rhMD2 interaction: GST-Tat 1–101 (0.1 μM)
were pre-incubated for 1 h with PBS (control) or with increasing amounts of soluble rhMD2, rhTLR4-MD2, rhTLR4 or rhCD14 before incubation
with the coated rhMD2. Binding of Tat to rhMD2 was analyzed as described above by measuring OD at 450 nm. The data represent OD at 450
nm and are representative of one of three independent experiments.
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showed the co-detection of Tat and TLR4 only in TLR4-
MD2 expressing cells. Comparison of the dissociation
constant values K0.5 of Tat-TLR4-MD2 (10
-9 M) and Tat-
MD2 (4.10-9 M), showed that K0.5 of Tat-TLR4-MD2 was
2.5 times smaller than that of Tat-MD2. This higher affin-
ity of Tat for TLR4-MD2 complex may be due to a better
stabilization of Tat interactions with the TLR4-MD2 com-
plex than with the MD2 alone. On the other hand, it has
been shown that LPS recognizes MD2 with a dissociation
constant of about 2.3 10-6 M [36] a K0.5 value that is 500
times higher than that found for Tat-MD2. In addition,
while a direct interaction between LPS and CD14 has
been described in several reports [36-38], in our study, no
detectable interaction was found between Tat and CD14
neither in the solid phase nor in pull-down binding assays.
At functional level and in agreement with our biochem-
ical data, we showed that Tat protein and its N-terminal
fragment Tat 1–45 induced the production of TNF-α and
IL-10 in macrophages from wild type mice but not in
macrophages from mice genetically deficient for TLR4,
MD2 or CD14. While the importance of cell surface
expression of TLR4 and MD2 seems to be in line with
our biochemical data, results obtained with CD14 KO
mice seem to be in apparent contradiction if we consider
its inability to interact with Tat protein. This apparent
contradiction is amplified by the fact that anti-CD14 anti-
bodies, which continue to inhibit LPS activation, fail to
inhibit Tat-induced cytokine production. This apparent
discrepancy may be related to the importance of CD14 in
the expression of a biologically active TLR4 or its recruit-
ment at cholesterol rich domains corresponding to the
signalling platform [34]. Also, it is interesting to note that
anti-MD2 antibodies were able to block cytokine produc-
tion by LPS, while these same antibodies failed to inhibit
Tat-induced cytokines. These results, in association with
those obtained with MD2 KO mice, also underline the
role of MD2 in the trafficking and surface localization of
TLR4 as previously reported [39]. In addition the capacity
of LPS-RS, an antagonist known for its capacity to alter
MD2-TLR4 signalling [33], to inhibit Tat-induced cytokines
is also an additional argument for the recruitment of this
signalling pathway by HIV-1 Tat protein.
Figure 3 Analysis of Tat and- TLR4-MD2 labelling at the cell surface. HEK cells null or HEK-TLR4-MD2-CD14 were pre-incubated with GST-Tat
1–101 or GST-Tat 1–45 or control GST during 15 min. GST+/−Tat were labelled with an anti-GST antibodies (red). WGA-633 (blue) was used to
label the membrane of cells and DAPI (cyan) was used as a nuclear marker. Scale bars are represented right down of each images.
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Considering the crucial role of PRR in the anti-viral
immune defense, some viruses have evolved multiple
mechanisms to hijack the initial function of TLR to their
advantage so as to escape the control of the immune sys-
tem or to infect their targets. For example, the respiratory
syncytial virus (RSV) by its F protein, activates TLR4 to
induce pro-inflammatory response that is implicated in
the rapid viral clearence [40,41]. Interestingly, the rate of
viral clearence was significantly reduced in RSV infected
TLR4-deficient mice [40,42]. Similarly, MMTV envelope
glycoprotein also triggers TLR4 pathway to activate in one
hand, B-cells, the major target cells of the virus, and on
the other hand to induce the expression of the immunosu-
pressive cytokine IL-10 [43], thereby establishing an im-
munosuppression state favorable for both the inhibition of
anti-viral immune response and viral replication [44]. So,
unlike the antiviral role of TLR4 in the clearence of RSV
[40,42], MMTV and HIV-1 are able to hijack TLR4 path-
way to induce the production of IL-10, which contribute in
association with other immunosuppressive factors, as PD-1,
PD-L1 and IDO (indoleamine 2,3 dioxygenase) [45,46] to
divert efficient immune response and to the establishment
of persistent infections. In addition, several studies have
shown that in some conditions, IL-10 can synergise with in-
flammatory cytokines to enhance HIV-1 replication [47,48].
Interestingly, other viruses have developed strategies
to interfere with TLR pathway activation. For example,
vaccinia virus, by its A46R protein which shares a TIR-like
domain, interferes with the TLR pathway to block both
MyD88 dependent and independent signalling [49]. Simi-
larly, hepatitis C virus by its NS5A protein, forms insoluble
complexes with MyD88 and inhibits the activation of
the TLR4 pathway in murine macrophages [50]. Measles
virus by its hemagglutinin, interacts with TLR2 on human
monocytes and ativates the expression of CD150, that is
its own entry receptor. These reports indicate that TLR
can be hijacked by endogenous or viral ligands to promote
the establishment of a pathological state or to escape viral
containment.
Conclusions
Taken together, our results give the first description of a
direct, high affinity interaction between HIV-1 Tat protein
and TLR4/MD2. By hijacking this pathway, HIV-1, via
its early expressed Tat protein, contributes to the estab-
lishment of an abnormal hyper-activation of the immune
system via TNF-α and to the development of an immuno-
suppression state by the production of IL-10, a highly
immunosuppressive cytokine.
The understanding of the molecular and cellular mecha-
nisms by which HIV Tat protein hijack the TLR4-CD14-
MD2 receptor pathway represents a crucial interest for
understanding the mechanisms recruited by HIV-1 to
induce immunosuppression and for the development of
new therapeutic strategies for future treatments.
Methods
Monocyte isolation
PBMCs were isolated from buffy coat of healthy HIV-1-
negative donors by Ficoll density gradient. Briefly, PBMC
were counted and resuspended in a 60/30 complete
medium (60% AIMV, 30% Iscove; (Gibco)) containing
1% foetal calf serum (FCS), penicillin (100 IU/mL) and
streptomycin (100 μg/ml). Monocytes were separated
from lymphocytes by adherence to tissue culture plastic
(Beckton Dickinson). After an incubation of 1 h at 37°C
5% CO2, non-adherent cells were removed and adherent
cells (> 94% CD14+ by flow cytometric analysis) were
washed and cultured in 60/30 complete medium con-
taining 10% FCS, penicillin (100 IU/ml) and streptomycin
(100 μg/ml) before being used in the experiments.
Human embryonic kidney 293 cell line
Transfected HEK cell line stably expressing TLR4, TLR4-
CD14-MD2, TLR2-CD14 and non-transfected HEK cell
line (HEK Null) were purchased from Invivogen. HEK
Null and HEK-TLR4 cell lines were cultured in DMEM
supplemented with 10% FCS, normocin (100 μg/mL) and
blasticidin (10 μg/ml); while HEK TLR4-CD14-MD2 and
HEK TLR2-CD14 cell lines were grown in DMEM 10%
FCS, normocin (100 μg/ml), blasticidin (10 μg/ml) and
hygrogold (50 μg/ml) at 37°C and 5% CO2.
Primary mouse peritoneal macrophages and peritoneal
washes
C57BL/6 were purchased from Charles Rivers. C3H/HeN
and C3H/HeJ or Knockout (KO) mice C57BL/6: TLR4−/−,
TLR2−/−, TLR3−/−, TLR9−/−, CD14−/−, MD2−/− were
(See figure on previous page.)
Figure 4 Tat protein fails to stimulate TNF-α and IL-10 in macrophages from TLR4−/− MD2−/−, and CD14−/− mice. A-B) Tat induces
mTNFα and mIL-10 production in wt C57Bl/6 murine macrophages. Peritoneal macrophages (5.105/well) from wild type C57BL/6 mice were
stimulated for 24 h with increasing concentration of GST-Tat 1–101, GST-Tat 1–45, GST-Tat 30–72 or GST as control. LPS was used as a positive
control. C-F) TLR4, CD14 and MD2 cell surface membrane proteins are essential for TNF-α and IL-10 production by Tat. Macrophages were
isolated from wt mice or mice KO for TLR4, TLR2 (C-D) or CD14 or MD2 (E-F). The cells were stimulated with increasing concentrations of GST-Tat
1–101, GST-Tat 1–45 or GST as control. Positive control experiments were performed by using the following TLR ligands: LPS (TLR4-CD14-MD2)
and Pam3CsK4 (TLR2-CD14). G-H) Human monocytes were pretreated with blocking antibodies, anti-CD14 or anti-MD2 (0.1 - 1 μg/ml) for 60 min.
Cells were then stimulated with GST or GST-Tat 1–101 (100 nM). I-J) TNF-α and IL-10 production in peritoneal washes from wt (I) or TLR4 KO
mice (J) injected with Tat protein. The data represent means +/− SD of three independent experiments.
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obtained from (CNRS, Orléans, France). This study was
conducted in accordance with the EU regulations and
with the French national chart for ethics of animal experi-
ments (articles R214-87 to 90 of the code rural). The
protocol was approved by the committee on the ethics
animal experiments of the Region Midi Pyrenée and by
IFR 150 (permit numbers: 04-U563-DG-06 and MP/18/26/
04/04). To minimize suffering, all animals were handeled
under anesthezia. Primary macrophages were isolated as
previously described [51]. Briefly, mice were injected intra
peritoneally with 1 ml of thioglycolate medium 3% (Bio-
merieux). Three days later, the mice were sacrificed and
macrophages were recovered by peritoneal washes and
then enriched by adherence selection for 1 h in complete
medium (DMEM supplemented with or without 2% FCS,
penicillin (100 IU/ml) and streptomycin (100 μg/ml). Iso-
lated macrophages were characterized by FACS analysis
for the expression of CD11b+. Primary macrophages and
peritoneal washes were obtained from two groups of mice.
Wt (3 animals) and TLR4 KO (3 animals) mice were
injected intraperitoneally with 100 μg of Gst-Tat at days 0,
1 and 3. 24 h after the last injection peritoneum was
washed with 5ml of PBS and cytokines were quantified.
Tat protein and TLR ligands
Recombinant HIV-1 Tat protein1-86 was obtained from
“Agence Nationale de la Recherche sur le SIDA” (Paris,
France). Synthetic Tat was obtained from E Loret (CNRS
Marseille). Recombinant GST and deleted Tat mutant
proteins were produced in our laboratory as previously
described [11]. The level of endotoxin was assessed using
the LAL assay (Bio-Sepra, France). All these recombinant
proteins contained less than 0.3 EU/μg, the limit of
detection of this test. LPS from E. coli, serotype R515
was purchased from Alexis biochemicals. Pam3CsK4 and
LPS-RS from R Sphaeroides, were obtained from Invivo-
Gen (San Diego, CA). Human IFN-γ was purchased from
eBioscience.
Antibodies and chemical inhibitors
For inhibition experiments: anti-human TLR4 (clone
HTA125), anti-TLR2 (clone TL2.1), anti-CD14 (clone
61D3) and mouse IgG2a isotype were obtained from
eBioscience. Anti-CD14 (clone RMO52 and clone MY4)
and mouse IgG isotype controls were from Beckman
Coulter; anti-MD2 (clone 288307) was from R&D Systems.
Mab anti-Tat antibodies were obtained from ANRS (Paris).
For confocal imaging and flow cytometry analysis: goat
anti-hTLR4 was from R&D System. Unlabelled mouse
anti-hTLR4 and labelled mouse anti-hTLR4-PE were
from eBioscience. Alexa 488 or 555 labelled IgG against
rabbit and goat IgG respectively, were from Invitrogen.
For western blot analysis, recombinant hMD2, rhCD14
and rhTLR4-MD2, monoclonal anti-hMD2 and anti-
hTLR4 were from R&D systems. Mabs CD14 (MEM-18)
was from Santa Cruz Biotechnology.
Cytokine detection by ELISA
Adherent monocytes (106/well), murine macrophages
(5.105/well) or HEK cells (5.105/well) were washed 3 times
with cold PBS. Cells were then cultured in the presence of
1% FCS. After 24 h of cell treatment, the supernatants
were collected and analyzed for human and mouse
TNF-α and IL-10. Cytokine amounts were determined
using ELISA kits from BD Biosciences and R&D Systems
according to the manufacturers’ instructions.
Confocal microscopy
HEK cells were grown on 12-mm round coverslides at
60–80 % confluence. They were then incubated with
GST-Tat (100 nM) for 15 min. After stimulation and
washing with PBS, cells were fixed with 4% paraformalde-
hyde-PBS for 10 min. After 3 washes, they were incubated
with 50 mM of NH4Cl for quenching. This step saturated
free aldehydes to inhibit auto-fluorescence. After extensive
washing, the cells were saturated with PBS-BSA 5% for 30
min. For colocalization experiments, GST-Tat and TLR4
proteins were labelled for 45 min at room temperature
with 10 μg/ml of mouse (Mab anti-Tat) or goat primary
polyclonal anti TLR4 antibodies. After washes, Tat and
TLR4 antibodies were labelled with the corresponding
secondary antibodies: Alexa Fluor-488 or Alexa Fluor-
555-conjugated antibodies directed against mouse or
goat immunoglobulin G (1/500) for 45 min at room
temperature. After three washes with PBS or PBS-MgCl2
150 mM, cell nuclei were stained at room temperature
with DAPI or chromomycin A3 in PBS-MgCl2 150 mM
for 1h. The images were taken with a confocal microscope
(Zeiss Axiomager LSM 710 META scanning unit and a
1.4NA × 63 objective). Cellular localization were analyzed
and processed with ImageJ.
GST pull-down and Co-immunoprecipitation assays
For GST pull-down, equal amounts of GST, GST-Tat 1–45,
GST-Tat 30–72 or GST-Tat 1–101 proteins coupled to
glutathione agarose beads were saturated with BSA
(250 μg/ml) for 2 h at 4°C. After washing (Tris–HCl 20
mM, NaCl 150 mM), agarose fixed proteins were incubated
with 1 μg of TLR4-MD2, MD2 or CD14 soluble recom-
binant human proteins (R&D Systems) or total cellular
extracts (500 μg) from HEK 293 or HEK 293-TLR4-
MD2-CD14 cells. The beads were then washed exten-
sively with Tris–HCl 20 mM, NaCl 150 mM, NP-40 0.5%,
PMSF 0.5 mM, leupeptin 10 μg/mL, Na3VO4 0.2 mM,
NaF 0.05 mM and the presence of retained TLR4, MD2 or
CD14 proteins was analyzed by SDS-PAGE and western
blot using specific antibodies. Recombinant human MD2,
TLR4-MD2, TLR4 or CD14 were coated at the indicated
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concentrations in 96 well plates for 24 h at 4°C. After
washing with PBS-0.05% Tween20, wells were saturated
with PBS-0.05% Tween 20, 5% non-fat milk for 1 h at 37°C.
After 3 washes, various amounts of GST, GST-Tat 1–101
or Tat deleted mutants were incubated for 2 h at 37°C.
For competition assays, GST-Tat or its deleted mutants
previously incubated for 1 h at 37°C with different ligands
were added to compete with the coated proteins (MD2 or
TLR4-MD2) in the wells for an additional 2 h. After wash-
ing, binding was detected by anti-GST (1/500) or monoclo-
nal anti-Tat antibodies (10 μg/ml) as described [9].
Statistical tests
All statistical analyses used the Student’s t-test, unpaired
for normal distribution, for at least three independent
experiments. Differences were considered significant at
p values < 0.05. Microsoft Excel and Prism were used to
construct the plots and measure means, standard deviations
and p values.
Additional files
Additional file 1: Figure S1. LPS-induced TNF-α and IL-10 is TLR4-
dependent. Monocytes were pretreated or not with increasing amounts of
blocking antibodies against TLR4 or TLR2 or isotype control for 1h before
stimulation by LPS 1 ng/mL. TNF-α and IL-10 production were quantified in
the culture supernatants by ELISA. Data represent means +/− SD (n=3).
Additional file 2: Figure S2. Characterization of recombinant proteins.
A) Equal amounts (1μg) of recombinant GST-Tat proteins were separated
by SDS-PAGE at 10% and stained by coomassie blue dye. B) recombinant
GST-Tat proteins analysis by western blot. Proteins were labeled by using
a monoclonal anti-Tat directed against the N-terminal region 1–15. C)
Recombinant TLR4, TLR4-MD2, MD2, CD14 proteins were separated by
SDS-PAGE at 10% and stained by coomassie blue dye.
Additional file 3: Figure S3. Tat interacts specifically and with high
affinity with MD2 and TLR4-MD2. A-B) Increasing amounts of rhMD2 were
coated in the wells. After incubation with a constant amount of GST-Tat
1–101 or GST-Tat 1–45 (1 μM), the binding of Tat to rhMD2 was detected
by using anti-GST antibodies (1/500). The data represent OD at 450 nm
+/− SD (triplicate) and are representative of one of three independent
experiments. C-D) Increasing concentrations of GST-Tat 1–101 or GST-Tat
1–45 were incubated for 2 h with 10-2 μg/mL of coated rhMD2. The data
represent OD at 450 nm +/− SD (triplicate) and are representative of one
of three independent experiments. E) rhMD2 and rhTLR4-MD2 compete
for Tat-rhMD2 interaction: GST-Tat 1–101 and 1–45 (0.1 μM) were pre-
incubated for 1 h with PBS (control) or with increasing amounts of
soluble rhTLR4-MD2, rhTLR4 or rhCD14 before incubation with the
coated rhMD2. Binding of Tat to rhMD2 was analyzed as described above
by measuring OD at 450 nm. Data represent mean +/− SD (n 33).
Additional file 4: Figure S4. Tat protein fails to stimulate TNF-α and
IL-10 in macrophages from TLR4−/− MD2−/−, and CD14−/− mice.
Macrophages were isolated from Wt mice (C3H/HeN) or mice deficient
for TLR4 signalling (C3H/HeJ). The cells were stimulated with increasing
concentrations of Tat 1–86, GST-Tat 1–101, GST-Tat 1–45, GST as control
or LPS. Mouse TNF-α and IL-10 production were determined by ELISA.
Data representative of three independent experiments (mean +/− SD).
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